Versiti Clinical Trials Services Partners with 4D Path to Accelerate Personalized Cancer Treatment Development

The AI-driven platform delivers tumor treatment predictive biomarkers to oncology researchers faster, more accurately, and at scale.

MILWAUKEE & NEWTON, Mass.--(BUSINESS WIRE)--Versiti Clinical Trials Services (VCTS) has launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments. The collaboration makes 4D Path's Q-Plasia OncoReader (QPOR™) platform available to pharmaceutical companies and clinical research organizations working with VCTS, giving them powerful new tools to understand how individual cancers respond to treatment.

QPOR™ transforms routine biopsy images into clear treatment predictive biomarkers that reveal how tumors and immune systems interact. The physics-inspired, AI-driven deterministic platform delivers these insights faster and at lower cost than traditional methods, helping researchers make critical decisions earlier in the development process. The QPOR™ platform is available to VCTS clients immediately.

"Every day matters when we're developing treatments that could save lives," Chris Miskel, President and CEO of Versiti, says. "This partnership gives our clients the speed and precision they need to bring personalized cancer therapies to patients who can no longer wait. We're seeing a deeper understanding of how individual cancers behave, with unprecedented clarity that wasn't possible before."

The QPOR™ platform works across cancers, providing robust, consistent, and reproducible results that meet regulatory standards. Clinical trial sponsors gain biologically explainable, treatment predictive insights that speed decision-making while reducing costs. For patients, this means potentially faster access to treatments tailored to their specific cancer.

"VCTS shares our commitment to making precision medicine accessible and practical," said Tathagata Dasgupta, founder, president, and CTO of 4D Path. "Together, we're giving researchers the clarity and insights they need to develop better treatments faster, without special processing or added complexity."

The partnership strengthens VCTS's position as a leader in oncology clinical trials, offering clients a comprehensive platform that combines proven trial management expertise with breakthrough analytical capabilities.

About Versiti Clinical Trials Services

Versiti Clinical Trials Services, a division of Versiti Blood Health, Inc., is dedicated to advancing life sciences research and improving patient outcomes through innovative clinical study support services. We collaborate with healthcare professionals, research institutions, and industry partners to develop life-changing solutions. Our commitment to scientific excellence, patient-centered care, and ethical research practices drives us to explore groundbreaking solutions for a healthier future.

Learn more at versiticlinicaltrials.org and on LinkedIn.

About 4D Path

4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications— bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.

For additional information, please visit www.4dpath.com or follow 4D Path on LinkedIn.